FIELD: pharmaceutical chemistry.
SUBSTANCE: invention relates to pharmaceutical chemistry and is the use of (S)–7–(2–metoxy–3,5–dimethylpyridine–4–il)–1–(tetrahydrofuran–3–il)–1N–pyrazolo[4,3–]quinoline-4(5N)-one of formula (I) or a pharmaceutically acceptable salt thereof for the treatment of dementia with Lewy bodies.
EFFECT: application of compound of formula (I) for treatment of dementia with Lewy bodies.
1 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AGENT FOR TREATMENT OF DEMENTIA, WHICH IS COMBINATION OF PYRAZOLOQUINOLINE DERIVATIVE AND MEMANTINE | 2018 |
|
RU2784428C2 |
| PENTACYCLIC COMPOUND | 2018 |
|
RU2754557C1 |
| COMPOSITIONS CONTAINING VORTIOXETINE AND DONEPEZIL | 2013 |
|
RU2635528C2 |
| SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-a]PYRIMIDINE-2,6-DIAMINES, SEROTONIN 5-HT RECEPTOR ANTAGONISTS, METHODS OF PRODUCING AND USING SAID COMPOUNDS | 2010 |
|
RU2421456C1 |
| ORGANIC COMPOUNDS | 2015 |
|
RU2709786C2 |
| COMPOSITION FOR TREATING OR PREVENTING NEURODEGENERATIVE DISORDERS | 2012 |
|
RU2699038C2 |
| PENTACYCLIC COMPOUND SALT AND CRYSTAL THEREOF | 2020 |
|
RU2820938C2 |
| AGONISTS OF 5-HT4-RECEPTORS FOR TREATING DEMENTIA | 2011 |
|
RU2569733C2 |
| LEUCINE, ACETYLLECINE AND RELATED ANALOGUES FOR TREATMENT OF DISEASE | 2020 |
|
RU2815373C2 |
| LIGAND WITH WIDE RANGE OF SIMULTANEOUS RECEPTOR ACTIVITY, PHARMACEUTICAL COMPOSITION, METHOD OF PREPARING SAID COMPOSITION AND MEDICINAL AGENT | 2008 |
|
RU2374245C1 |
